Barbier, Liese http://orcid.org/0000-0003-1786-2080
Simoens, Steven http://orcid.org/0000-0002-9512-2005
Vulto, Arnold G. http://orcid.org/0000-0002-8439-2800
Huys, Isabelle http://orcid.org/0000-0002-4738-8298
Funding for this research was provided by:
University Medical Center Rotterdam
Article History
First Online: 15 October 2020
Declarations
:
: This manuscript was funded by the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund).
: IH, SS, and AGV are founders of the MABEL Fund. AGV is involved in consulting, advisory work, and speaking engagements for a number of companies, including AbbVie, Accord, Amgen, Biogen, Fresenius/Kabi, Medicines for Europe, Pfizer/Hospira, Mundipharma, Roche, Novartis, Sandoz, and Boehringer Ingelheim. SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer, and MSD. He has participated in advisory board meetings for Pfizer and Amgen and contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma, and Pfizer. IH and LB have no conflicts of interest that are directly relevant to the content of this article.
: Ethics approval was obtained from the Education-Guidance Committee for Medical Ethics in delegation of the Ethics Committee of UZ/KU Leuven (MP001375, Belgium).
: All interviewees provided their written informed consent to participate in the study.
: All interviewees provided their written informed consent for us to use the coded data of their interview for publication in scientific journals.
: The interview data are not publicly available as they contain information that could compromise interviewees’ privacy and consent.
: Not applicable.